Clinical Trial: Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)

U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07629596) titled 'Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)' on May 20.

Brief Summary: This is an open lable and single arm study designed to evaluate the safety, PK and PD of Arnovie101 in B cell-mediated Autoimmune Disease

Study Start Date: April 07

Study Type: INTERVENTIONAL

Condition: Systemic Lupus Erythematosus Autoimmune Hemolytic Anemia (AIHA)

Intervention: DRUG: Arnovie101 Infusion Intravenous

Dosing will begin at a lower dose level and may be escalated to dose levels considered safe and pote...